QSARs, data and error in the modern age of drug discovery

Current Topics in Medicinal Chemistry

Volumn 12, Issue 17, 2012, Pages 1896-1902

  Kramer, Christian ^a   Lewis, Richard ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Drug discovery; Error analysis; High throughput screenings; Public databases; QSAR

Indexed keywords

ACCURACY; ANALYTICAL ERROR; ARTICLE; CHEMICAL ANALYSIS; DATA BASE; DRUG BINDING SITE; DRUG DESIGN; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; LIGAND BINDING; MODEL; MOLECULAR DOCKING; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; TOXICOLOGY;

DATABASES, PROTEIN; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RESEARCH DESIGN;

EID: 84872223600     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612804547380     Document Type: Article

References (30)

1. Nicola, G.; Liu, T.; Gilson, M.K. Public Domain Databases for Medicinal Chemistry. J. Med. Chem., 2012, 55, 6987-7002.
2. Gaulton, A.; Bellis, L.J.; Bento, A.P.; Chambers, J.; Davies, M.; Hersey, A.; Light, Y.; McGlinchey, S.; Michalovich, D.; Al-Lazikani, B.; Overington, J.P. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res., 2011, 40, D1100-D1107.
3. Wang, Y.; Xiao, J.; Suzek, T.O.; Zhang, J.; Wang, J.; Zhou, Z.; Han, L.; Karapetyan, K.; Dracheva, S.; Shoemaker, B.A.; Bolton, E.; Gindulyte, A.; Bryant, S.H. PubChem's BioAssay Database. Nucleic Acids Res., 2012, 40, D400-412.
4. Liu, T.; Lin, Y.; Wen, X.; Jorissen, R. N.; Gilson, M. K. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res., 2007, 35, D198-201.
5. Young, D.; Martin, T.; Venkatapathy, R.; Harten, P. Are the Chemical Structures in Your QSAR Correct? QSAR Comb. Sci., 2008, 27, 1337-1345.
6. Fourches, D.; Muratov, E.; Tropsha, A. Trust, but verify: on the importance of chemical structure curation in cheminformatics and QSAR modeling research. J. Chem. Inf. Model., 2010, 50, 1189-1204.
7. Kramer, C.; Kalliokoski, T.; Gedeck, P.; Vulpetti, A. The Experimental Uncertainty of Heterogeneous Public Ki Data. J. Med. Chem., 2012, 55, 5165-5173.
8. Dearden, J.C.; Cronin, M.T.D.; Kaiser, K.L.E. How not to develop a quantitative structure-activity or structure-property relationship (QSAR/QSPR). SAR QSAR Environ. Res., 2009, 20, 241-266.
9. Ioannidis, J.P.A. Why Most Published Research Findings Are False. PLoS Medicine, 2005, 2, e124.
10. Mendgen, T.; Steuer, C.; Klein, C.D. Privileged Scaffolds or Promiscuous Binders: A Comparative Study on Rhodanines and Related Heterocycles in Medicinal Chemistry. J. Med. Chem., 2012, 55, 743-753.
11. Baell, J.B.; Holloway, G.A. New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays. J. Med. Chem., 2010, 53, 2719-2740.
12. Williams, A.J.; Harland, L.; Groth, P.; Pettifer, S.; Chichester, C.; Willighagen, E.L.; Evelo, C.T.; Blomberg, N.; Ecker, G.; Goble, C.; Mons, B. Open PHACTS: semantic interoperability for drug discovery. Drug Discov. Today, 2012 in the press.
13. Maglott, D.; Ostell, J.; Pruitt, K.D.; Tatusova, T. Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res., 2005, 33, D54-58.
14. Stouch, T.R.; Kenyon, J.R.; Johnson, S.R.; Chen, X.-Q.; Doweyko, A.; Li, Y. In silico ADME/Tox: why models fail. J. Comput. Aided Mol. Des., 2003, 17, 83-92.
15. Williams, A.J.; Ekins, S. A quality alert and call for improved curation of public chemistry databases. Drug Discov. Today, 2011, 16, 747-750.
16. Bains, W.; Basman, A.; White, C. HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study. Prog. Biophys. Mol. Biol., 2004, 86, 205-233.
17. Nigsch, F.; Lounkine, E.; McCarren, P.; Cornett, B.; Glick, M.; Azzaoui, K.; Urban, L.; Marc, P.; Müller, A.; Hahne, F.; Heard, D.J.; Jenkins, J.L. Computational methods for early predictive safety assessment from biological and chemical data. Expert Opin. Drug Met., 2011, 7, 1497-1511.
18. Steger-Hartmann, T.; Pognan, F.; Sanz, F.; Diaz, C.A. In silico prediction of in vivo toxicities (eTox)-The Innovative Medicines Initiative Approach. Tox. Lett., 2009, 189, Supplement, S258.
19. Altman, R.B. Translational Bioinformatics: Linking the Molecular World to the Clinical World. Clin. Pharmacol. Ther., 2012, 91, 994-1000.
20. Krejsa, C.M.; Horvath, D.; Rogalski, S.L.; Penzotti, J.E.; Mao, B.; Barbosa, F.; Migeon, J.C. Predicting ADME properties and side effects: the BioPrint approach. Curr. Opin. Drug. Discov. Devel., 2003, 6, 470-480.
21. Fliri, A.F.; Loging, W.T.; Thadeio, P.F.; Volkmann, R.A. Analysis of drug-induced effect patterns to link structure and side effects of medicines. Nat. Chem. Biol., 2005, 1, 389-397.
22. Kramer, C.; Beck, B.; Clark, T. Insolubility classification with accurate prediction probabilities using a MetaClassifier. J. Chem. Inf. Model., 2010, 50, 404-414.
23. Davis, A.; Stgallay, S.; Kleywegt, G. Limitations and lessons in the use of X-ray structural information in drug design. Drug Discov. Today, 2008, 13, 831-841.
24. Hartshorn, M.J.; Verdonk, M.L.; Chessari, G.; Brewerton, S.C.; Mooij, W.T.M.; Mortenson, P.N.; Murray, C.W. Diverse, High-Quality Test Set for the Validation of Protein-Ligand Docking Performance. J. Med. Chem., 2007, 50, 726-741.
25. Dunbar, J.B., Jr.; Smith, R.D.; Yang, C.-Y.; Ung, P.M.-U.; Lexa, K.W.; Khazanov, N.A.; Stuckey, J.A.; Wang, S.; Carlson, H.A. CSAR benchmark exercise of 2010: selection of the protein-ligand complexes. J. Chem. Inf. Model., 2011, 51, 2036-2046.
26. Allen, F.H. The Cambridge Structural Database: a quarter of a million crystal structures and rising. ActaCryst. B., 2002, 58, 380-388.
27. Bernstein, F.C.; Koetzle, T.F.; Williams, G.J.; Meyer, E.F., Jr; Brice, M.D.; Rodgers, J.R.; Kennard, O.; Shimanouchi, T.; Tasumi, M. The Protein Data Bank: a computer-based archival file for macromolecular structures. J. Mol. Biol., 1977, 112, 535-542.
28. Jenkins, J.L. Large-Scale QSAR in Target Prediction and Phenotypic HTS Assessment. Mol. Inf., 2012, 31, 508-514.
29. Bajorath, J.; Peltason, L.; Wawer, M.; Guha, R.; Lajiness, M.S.; Van Drie, J.H. Navigating structure-activity landscapes. Drug Discov. Today, 2009, 14, 698-705.
30. Iyer, P.; Dimova, D.; Vogt, M.; Bajorath, J. Navigating High-Dimensional Activity Landscapes: Design and Application of the Ligand-Target Differentiation Map. J. Chem. Inf. Model., 2012, 52, 1962-1969.